Factors associated with engraftment success of patient-derived xenografts of breast cancer

Breast Cancer Res. 2024 Mar 21;26(1):49. doi: 10.1186/s13058-024-01794-w.

Abstract

Background: Patient-derived xenograft (PDX) models serve as a valuable tool for the preclinical evaluation of novel therapies. They closely replicate the genetic, phenotypic, and histopathological characteristics of primary breast tumors. Despite their promise, the rate of successful PDX engraftment is various in the literature. This study aimed to identify the key factors associated with successful PDX engraftment of primary breast cancer.

Methods: We integrated clinicopathological data with morphological attributes quantified using a trained artificial intelligence (AI) model to identify the principal factors affecting PDX engraftment.

Results: Multivariate logistic regression analyses demonstrated that several factors, including a high Ki-67 labeling index (Ki-67LI) (p < 0.001), younger age at diagnosis (p = 0.032), post neoadjuvant chemotherapy (NAC) (p = 0.006), higher histologic grade (p = 0.039), larger tumor size (p = 0.029), and AI-assessed higher intratumoral necrosis (p = 0.027) and intratumoral invasive carcinoma (p = 0.040) proportions, were significant factors for successful PDX engraftment (area under the curve [AUC] 0.905). In the NAC group, a higher Ki-67LI (p < 0.001), lower Miller-Payne grade (p < 0.001), and reduced proportion of intratumoral normal breast glands as assessed by AI (p = 0.06) collectively provided excellent prediction accuracy for successful PDX engraftment (AUC 0.89).

Conclusions: We found that high Ki-67LI, younger age, post-NAC status, higher histologic grade, larger tumor size, and specific morphological attributes were significant factors for predicting successful PDX engraftment of primary breast cancer.

Keywords: Artificial intelligence; Breast cancer; Deep learning; Engraftment; Morphometrics; Neoadjuvant chemotherapy; Patient-derived xenograft; Triple-negative breast cancer; Young age.

MeSH terms

  • Animals
  • Artificial Intelligence
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / therapy
  • Disease Models, Animal
  • Female
  • Heterografts
  • Humans
  • Xenograft Model Antitumor Assays